Alopecia areata. Pathogenesis, diagnosis, and therapy
- PMID: 11702308
- DOI: 10.2165/00128071-200001020-00004
Alopecia areata. Pathogenesis, diagnosis, and therapy
Abstract
Alopecia areata is a common form of non-scarring alopecia that appears equally in males and females of any age, although children and adolescents are more commonly affected. The disorder is usually characterized by limited alopecic patches on the scalp, but more severe forms may affect the entire scalp (alopecia totalis) or body (alopecia universalis). Characteristic nail changes may also accompany hair loss. Alopecia areata has been linked with certain human leukocyte antigen (HLA) class II alleles, indicating a probable autoimmune etiology. Current research implicates T lymphocytes in the pathogenetic mechanism of disease. Other autoimmune diseases are also linked with alopecia areata. The diagnosis of alopecia areata is usually made clinically, although a biopsy is diagnostic for this condition. Treatment is challenging and aims at the regrowth of hair in affected individuals. Intralesional corticosteroid injections are widely used in mild disease. Topical anthralin and minoxidil may also be clinically efficacious. Topical sensitizers, such as squaric acid dibutlyester and diphenyl-cyclopropenone, are sometimes employed. Various therapies for the disease may have efficacy in different patients, making a universal treatment algorithm difficult to implement. Patients should be handled on an individual basis, with the final outcome based on the cosmetic regrowth of hair. Maintenance therapy is also important in patients that do achieve acceptable regrowth, necessitating a highly motivated patient and good rapport with the treating physician.
Similar articles
-
Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients.Pediatr Dermatol. 2018 Nov;35(6):817-820. doi: 10.1111/pde.13703. Epub 2018 Oct 18. Pediatr Dermatol. 2018. PMID: 30338548
-
Childhood Alopecia Areata: An Overview of Treatment and Recent Patents.Recent Pat Inflamm Allergy Drug Discov. 2020;14(2):117-132. doi: 10.2174/1872213X14999200728145822. Recent Pat Inflamm Allergy Drug Discov. 2020. PMID: 32723274 Review.
-
Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.J Cosmet Dermatol. 2020 Sep;19(9):2411-2414. doi: 10.1111/jocd.13588. Epub 2020 Jul 21. J Cosmet Dermatol. 2020. PMID: 32621407
-
An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.J Drugs Dermatol. 2018 Aug 1;17(8):914-917. J Drugs Dermatol. 2018. PMID: 30124734 Review.
-
Topical and intralesional therapies for alopecia areata.Dermatol Ther. 2011 May-Jun;24(3):355-63. doi: 10.1111/j.1529-8019.2011.01419.x. Dermatol Ther. 2011. PMID: 21689245 Review.
Cited by
-
Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.JCI Insight. 2021 Apr 8;6(7):e142205. doi: 10.1172/jci.insight.142205. JCI Insight. 2021. PMID: 33830087 Free PMC article.
-
Alopecia: possible causes and treatments, particularly in captive nonhuman primates.Comp Med. 2009 Feb;59(1):18-26. Comp Med. 2009. PMID: 19295051 Free PMC article. Review.
-
Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata.Clin Exp Immunol. 2004 Mar;135(3):398-408. doi: 10.1111/j.1365-2249.2003.02380.x. Clin Exp Immunol. 2004. PMID: 15008971 Free PMC article.
-
Utility of dermoscopy in alopecia areata.Indian J Dermatol. 2011 Jul;56(4):407-11. doi: 10.4103/0019-5154.84768. Indian J Dermatol. 2011. PMID: 21965849 Free PMC article.
-
Patches of hair loss on the scalp.Can Fam Physician. 2006 Aug;52(8):957, 960. Can Fam Physician. 2006. PMID: 17273496 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials